Protease-Cleavable Linkers Modulate the Anticancer Activity of Noninternalizing Antibody-Drug Conjugates

Bioconjugate Chemistry

Volumn 28, Issue 7, 2017, Pages 1826-1833

  Dal Corso, Alberto ^a   Cazzamalli, Samuele ^a   Gébleux, Rémy ^a   Mattarella, Martin ^b   Neri, Dario ^a  

^a ETH ZURICH   (Switzerland)

^b PHILOCHEM AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; DRUG PRODUCTS; MASS SPECTROMETRY; PEPTIDES; TARGETED DRUG DELIVERY; TUMORS;

ANTIBODY-DRUG CONJUGATES; ANTICANCER ACTIVITIES; BIOPHARMACEUTICALS; CANCER CELLS; CYTOTOXIC AGENTS; DI-PEPTIDES; GROWING BODIES; IN-VIVO; ISOFORMS; TENASCIN;

ANTIBODIES;

AMINO ACID; ANTIBODY DRUG CONJUGATE; ANTINEOPLASTIC AGENT; DIPEPTIDE; PROTEINASE; TENASCIN; VEDOTIN; ALANINE; AMINOBENZOIC ACID DERIVATIVE; ANTIBODY CONJUGATE; AURISTATIN; OLIGOPEPTIDE; PEPTIDE HYDROLASE; VALINE;

AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENCY; DRUG RELEASE; DRUG STABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; SQUAMOUS CELL CARCINOMA; ANIMAL; CHEMISTRY; EXTRACELLULAR MATRIX; GENETICS; IMMUNOLOGY; METABOLISM;

ALANINE; AMINOBENZOATES; ANIMALS; ANTINEOPLASTIC AGENTS; DIPEPTIDES; EXTRACELLULAR MATRIX; HUMANS; IMMUNOCONJUGATES; MICE; OLIGOPEPTIDES; PEPTIDE HYDROLASES; TENASCIN; VALINE;

EID: 85025111702     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.7b00304     Document Type: Article

References (41)

1. van der Veldt, A. A., Hendrikse, N. H., Smit, E. F., Mooijer, M. P., Rijnders, A. Y., Gerritsen, W. R., van der Hoeven, J. J., Windhorst, A. D., Lammertsma, A. A., and Lubberink, M. (2010) Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients Eur. J. Nucl. Med. Mol. Imaging 37, 1950-1958 10.1007/s00259-010-1489-y
2. Bosslet, K., Straub, R., Blumrich, M., Czech, J., Gerken, M., Sperker, B., Kroemer, H. K., Gesson, J. P., Koch, M., and Monneret, C. (1998) Elucidation of the mechanism enabling tumor selective prodrug monotherapy Cancer Res. 58, 1195-1201
3. Alley, S. C., Okeley, N. M., and Senter, P. D. (2010) Antibody-drug conjugates: targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14, 529-537 10.1016/j.cbpa.2010.06.170
4. Gerber, H.-P., Koehn, F. E., and Abraham, R. T. (2013) The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics Nat. Prod. Rep. 30, 625-639 10.1039/c3np20113a
5. Chu, Y.-W. and Polson, A. (2013) Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia Future Oncol. 9, 355-368 10.2217/fon.12.189
6. Chari, R. V., Miller, M. L., and Widdison, W. C. (2014) Antibody-drug conjugates: an emerging concept in cancer therapy Angew. Chem., Int. Ed. 53, 3796-3827 10.1002/anie.201307628
7. de Goeij, B. E. C. G. and Lambert, J. M. (2016) New developments for antibody-drug conjugate-based therapeutic approaches Curr. Opin. Immunol. 40, 14-23 10.1016/j.coi.2016.02.008
8. Senter, P. D. and Sievers, E. L. (2012) The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma Nat. Biotechnol. 30, 631-637 10.1038/nbt.2289
9. Dorywalska, M., Dushin, R., Moine, L., Farias, S. E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Casas, M. G., and Tran, T. T. et al. 2016, Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design Mol. Cancer Ther. 15, 958-970 10.1158/1535-7163.MCT-15-1004
10. Bander, N. H. (2013) Antibody-drug conjugate target selection: critical factors Methods Mol. Biol. 1045, 29-40 10.1007/978-1-62703-541-5-2
11. Xu, S. (2015) Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates Pharm. Res. 32, 3577-3583 10.1007/s11095-015-1729-8
12. Yasunaga, M., Manabe, S., Tarin, D., and Matsumura, Y. (2011) Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue Bioconjugate Chem. 22, 1776-1783 10.1021/bc200158j
13. Yasunaga, M., Manabe, S., and Matsumura, Y. (2011) New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots Cancer Sci. 102, 1396-1402 10.1111/j.1349-7006.2011.01954.x
14. Bernardes, G. J., Casi, G., Trüssel, S., Hartmann, I., Schwager, K., Scheuermann, J., and Neri, D. (2012) A traceless vascular-targeting antibody-drug conjugate for cancer therapy Angew. Chem., Int. Ed. 51, 941-944 10.1002/anie.201106527
15. Perrino, E., Steiner, M., Krall, N., Bernardes, G. J., Pretto, F., Casi, G., and Neri, D. (2014) Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids Cancer Res. 74, 2569-2578 10.1158/0008-5472.CAN-13-2990
16. Gébleux, R. and Casi, G. (2016) Antibody-drug conjugates: Current status and future perspectives Pharmacol. Ther. 167, 48-59 10.1016/j.pharmthera.2016.07.012
17. Brack, S. S., Silacci, M., Birchler, M., and Neri, D. (2006) Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C Clin. Cancer Res. 12, 3200-3208 10.1158/1078-0432.CCR-05-2804
18. Heuveling, D. A., de Bree, R., Vugts, D. J., Huisman, M. C., Giovannoni, L., Hoekstra, O. S., Leemans, C. R., Neri, D., and van Dongen, G. A. (2013) Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients J. Nucl. Med. 54, 397-401 10.2967/jnumed.112.111310
19. Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A., and Neri, D. (2017) Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the sub-endothelial extracellular matrix Int. J. Cancer 140, 1670-1679 10.1002/ijc.30569
20. Barrett, A. J. (1980) Fluorimetric assays for cathepsin B and cathepsin H with methylcoumarylamide substrates Biochem. J. 187, 909-912 10.1042/bj1870909
21. Dubowchik, G. M. and Firestone, R. A. (1998) Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin Bioorg. Med. Chem. Lett. 8, 3341-3346 10.1016/S0960-894X(98)00609-X
22. Jain, N., Smith, S. W., Ghone, S., and Tomczuk, B. (2015) Current ADC Linker Chemistry Pharm. Res. 32, 3526-3540 10.1007/s11095-015-1657-7
23. Hochdörffer, K., Abu Ajaj, K., Schäfer-Obodozie, C., and Kratz, F. (2012) Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix J. Med. Chem. 55, 7502-7515 10.1021/jm300493m
24. Dal Corso, A., Caruso, M., Belvisi, L., Arosio, D., Piarulli, U., Albanese, C., Gasparri, F., Marsiglio, A., Sola, F., Troiani, S., Valsasina, B., Pignataro, L., Donati, D., and Gennari, C. (2015) Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers Chem.-Eur. J. 21, 6921-6929 10.1002/chem.201500158
25. Cazzamalli, S., Dal Corso, A., and Neri, D. (2017) Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma J. Controlled Release 246, 39-45 10.1016/j.jconrel.2016.11.023
26. Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., and Elliott, J. M. et al. 2009, Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection Cancer Res. 69, 2358-2364 10.1158/0008-5472.CAN-08-2250
27. Dijoseph, J. F., Dougher, M. M., Armellino, D. C., Kalyandrug, L., Kunz, A., Boghaert, E. R., Hamann, P. R., and Damle, N. K. (2007) CD20-specific antibody-targeted chemotherapy of non-Hodgkin's B-cell lymphoma using calicheamicin-conjugated rituximab Cancer Immunol. Immunother. 56, 1107-1117 10.1007/s00262-006-0260-5
28. Verma, V. A., Pillow, T. H., DePalatis, L., Li, G., Phillips, G. L., Polson, A. G., Raab, H. E., Spencer, S., and Zheng, B. (2015) The cryptophycins as potent payloads for antibody drug conjugates Bioorg. Med. Chem. Lett. 25, 864-868 10.1016/j.bmcl.2014.12.070
29. Dorywalska, M., Strop, P., Melton-Witt, J. A., Hasa-Moreno, A., Farias, S. E., Galindo Casas, M., Delaria, K., Lui, V., Poulsen, K., and Sutton, J. et al. 2015, Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy PLoS One 10, e0132282 10.1371/journal.pone.0132282
30. Tumey, L. N., Rago, B., and Han, X. (2015) In vivo biotransformations of antibody-drug conjugates Bioanalysis 7, 1649-1664 10.4155/bio.15.84
31. Shen, B. Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S. F., and Mai, E. et al. 2012, Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates Nat. Biotechnol. 30, 184-189 10.1038/nbt.2108
32. Mendelsohn, B. A., Barnscher, S. D., Snyder, J. T., An, Z., Dodd, J. M., and Dugal-Tessier, J. (2017) Investigation of Hydrophilic Auristatin Derivatives for Use in Antibody Drug Conjugates Bioconjugate Chem. 28, 371-381 10.1021/acs.bioconjchem.6b00530
33. Gébleux, R., Wulhfard, S., Casi, G., and Neri, D. (2015) Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates Mol. Cancer Ther. 14, 2606-2612 10.1158/1535-7163.MCT-15-0480
34. Casi, G. and Neri, D. (2015) Noninternalizing targeted cytotoxics for cancer therapy Mol. Pharmaceutics 12, 1880-1884 10.1021/mp500798y
35. Li, F., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., Nicholas, N. D., Okeley, N. M., Lyon, R. P., and Benjamin, D. R. et al. 2016, Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models Cancer Res. 76, 2710-2719 10.1158/0008-5472.CAN-15-1795
36. Pedretti, M., Soltermann, A., Arni, S., Weder, W., Neri, D., and Hillinger, S. (2009) Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer Lung Cancer 64, 28-33 10.1016/j.lungcan.2008.07.013
37. Schwager, K., Villa, A., Rösli, C., Neri, D., Rösli-Khabas, M., and Moser, G. (2011) A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer Head Neck Oncol. 3, 25 10.1186/1758-3284-3-25
38. Mårlind, J., Kaspar, M., Trachsel, E., Sommavilla, R., Hindle, S., Bacci, C., Giovannoni, L., and Neri, D. (2008) Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy Clin. Cancer Res. 14, 6515-6524 10.1158/1078-0432.CCR-07-5041
39. Frey, K., Fiechter, M., Schwager, K., Belloni, B., Barysch, M. J., Neri, D., and Dummer, R. (2011) Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions Exp. Dermatol. 20, 685-688 10.1111/j.1600-0625.2011.01314.x
40. Schliemann, C., Wiedmer, A., Pedretti, M., Szczepanowski, M., Klapper, W., and Neri, D. (2009) Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma Leuk. Res. 33, 1718-1722 10.1016/j.leukres.2009.06.025
41. Gutbrodt, K. L., Schliemann, C., Giovannoni, L., Frey, K., Pabst, T., Klapper, W., Berdel, W. E., and Neri, D. (2013) Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia Sci. Transl. Med. 5, 201ra118 10.1126/scitranslmed.3006221